By Billy Candra 
The Enduring Challenge: Secondary Cancers as a Leading Mortality Cause
Childhood cancer, while a devastating diagnosis, has seen remarkable improvements in survival rates over the past few decades. In the mid-1970s, the five-year survival rate for children with cancer hovered around 58%; today, thanks to relentless research and advancements in treatment protocols, it exceeds 85%. This triumph, however, has brought into sharper focus a new set of challenges: the late effects of cancer treatment. As more children survive into adulthood, the long-term health consequences of their intensive therapies become increasingly apparent. Among these, the development of a second primary cancer stands out as the most significant threat, often becoming the leading cause of mortality for these survivors, surpassing the risk of recurrence of their initial cancer.
Understanding the etiology of these secondary malignancies is paramount for developing effective prevention, screening, and treatment strategies. Historically, clinical focus has largely been on the direct impact of chemotherapy and radiation exposure, given their known mutagenic and carcinogenic properties. While the association between these treatments and increased risk has been well-established, the relative contributions of treatment, genetic predisposition, and even lifestyle factors, at a population level, remained largely unquantified. This knowledge gap left clinicians without a precise framework for individualized risk assessment and tailored follow-up care.
A Landmark Study: Quantifying Risk Factors
The St. Jude study addresses this critical gap by providing the first population-level attribution of risk factors for secondary cancers. "We found the burden of second cancer in survivors of childhood cancer is largely contributed by pediatric treatment exposures and genetic predisposition," stated corresponding author Yadav Sapkota, PhD, from the St. Jude Department of Epidemiology and Cancer Control. "We’ve known treatment exposures and genetics were associated with second cancer risk, but this is the first time we’ve been able to attribute the proportion of their contributions to that risk at the population level." This quantification marks a significant leap forward, moving beyond mere association to a clearer understanding of causality and magnitude.
The meticulous research compared data from over 10,000 survivors drawn from the St. Jude LIFE and CCSS cohorts, collectively representing the largest survivor cohort in North America. The richness of this combined dataset is unparalleled, encompassing detailed information on past treatment exposures, long-term health outcomes, comprehensive genetic profiles, various lifestyle factors, and, crucially, the presence or absence of a second primary cancer. Such extensive data allowed researchers to move beyond examining factors in isolation, instead enabling a sophisticated evaluation of their proportional contributions to secondary cancer development.
The St. Jude Children’s Research Hospital, founded in 1962 by Danny Thomas, has long been at the forefront of understanding and treating childhood catastrophic diseases. Its commitment to not just curing cancer but also ensuring the quality of life for survivors led to the establishment of pioneering long-term follow-up programs. The Childhood Cancer Survivor Study (CCSS), initiated in 1994, is a multi-institutional cohort study tracking over 35,000 survivors diagnosed between 1970 and 1999. The St. Jude Lifetime Cohort Study (St. Jude LIFE), launched in 2007, focuses on survivors treated at St. Jude, providing deeply phenotyped and genotyped data from thousands of individuals. These two studies, with their longitudinal data collection spanning decades and including detailed genetic sequencing, are uniquely positioned to conduct this type of high-impact research. Co-author Greg Armstrong, MD, MSCE, chair of the St. Jude Department of Epidemiology and Cancer Control, underscored this point, noting, "This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts, that in combination, have more than 12,000 survivors with genetic sequencing."
Radiation Exposure: A Historically Dominant Factor
The study confirmed the significant role of radiation exposure as a potent contributor to secondary cancer risk. It was identified as the most impactful factor, accounting for approximately 40% or more of the overall risk, depending on the specific type of secondary cancer. This finding aligns with decades of prior research documenting the long-term adverse effects of therapeutic radiation, particularly its role in inducing solid tumors such as breast cancer, thyroid cancer, and sarcomas. The mechanism involves radiation-induced DNA damage, which can lead to mutations and genomic instability in healthy cells within the irradiated field.
Recognition of radiation’s profound long-term toxicity has already spurred significant shifts in modern pediatric oncology. Over the past few decades, treatment protocols have continuously evolved, with a concerted effort to reduce radiation doses, limit irradiated fields, or entirely remove radiation exposure when alternative, equally effective treatments, such as targeted chemotherapy or immunotherapy, become available. For example, in conditions like Hodgkin lymphoma, where radiation was once a cornerstone of therapy, risk-adapted strategies now frequently allow for radiation-sparing approaches for many patients. The current study provides strong, data-driven validation for these ongoing efforts to minimize radiation exposure in contemporary childhood cancer treatments, reinforcing the importance of continued vigilance in optimizing therapeutic regimens to maximize cure rates while minimizing late effects.
Genetics vs. Chemotherapy: Redefining Conventional Wisdom
While the impact of radiation was relatively straightforward, the study uncovered more intricate relationships concerning chemotherapy and genetic predisposition. Chemotherapy, a broad category of drugs with diverse mechanisms of action, contributed between 8% and 35% of subsequent cancer risk, with variations depending on the type of cancer. The late effects of chemotherapy, including secondary leukemias (e.g., therapy-related acute myeloid leukemia) and solid tumors, have been well-described. However, the contribution of an individual’s inherent genetic makeup to secondary cancer risk in survivors has been less thoroughly explored and quantified at a population level.
To better understand this genetic predisposition, the researchers utilized a sophisticated approach involving both common and rare genetic variants. They examined hundreds of common genetic variants previously linked to cancer development in the general population, integrating this information into what is known as a polygenic risk score (PRS). Simultaneously, they assessed the impact of specific rare genetic variants that confer high cancer risk. The analysis of these variants in the St. Jude LIFE and CCSS participants revealed a profound insight: polygenic risk scores contributed to 5% to 37% of the risk for secondary cancers, a range that, for certain cancer types, rivaled or even surpassed the contribution of chemotherapy.
- Understanding Polygenic Risk Scores (PRS): Unlike single gene mutations that confer a high, often deterministic, risk for certain cancers (e.g., BRCA1/2 for breast and ovarian cancer), polygenic risk scores aggregate the effects of many common genetic variants, each individually having a small effect. When combined, these small effects can collectively influence an individual’s susceptibility to various diseases, including cancer. PRS offers a more comprehensive picture of an individual’s inherited risk beyond single high-risk genes. While polygenic risk scores are being developed for various diseases in the context of personalized medicine, their clinical utility in the general population is often limited by a lack of sufficient precision. However, within the specific and high-risk population of childhood cancer survivors, their predictive power appears to be considerably enhanced. Co-author Yutaka Yasui, PhD, from the St. Jude Department of Epidemiology and Cancer Control, commented, "Among survivors of childhood cancer and for estimating their risk of certain types of subsequent cancer, however, they may provide useful information in conjunction with therapy exposures."
The revelation that genetics can be as important, or even more important, than chemotherapy for some second cancers directly challenges long-held conventional wisdom in the field. Dr. Sapkota emphasized this paradigm shift: "Our findings showed that genetics can be equally or more important than chemotherapy in some second cancers, which is counter to conventional wisdom in the field." This finding suggests that a survivor’s inherent susceptibility, encoded in their DNA, plays a much more substantial role than previously appreciated, interacting with treatment exposures to determine their ultimate risk profile.
The Nuance of Lifestyle Factors
In contrast to radiation, chemotherapy, and genetics, lifestyle factors—such as diet and exercise—appeared to contribute comparatively less to secondary cancer risk in this study, accounting for a modest 1% to 6% of the risk. This finding, while seemingly counterintuitive given the well-established role of lifestyle in general cancer prevention, comes with an important caveat. The survivor cohorts in this study were primarily in their 20s and 30s. It is plausible that, at these relatively young ages, the cumulative effects of lifestyle choices on cancer risk may not yet have fully manifested. Many lifestyle-related cancers typically develop later in life after decades of exposure to risk factors.
Dr. Sapkota acknowledged this nuance: "We know healthy lifestyle choices are important for survivors. In this study, we focused only on the risk of second cancers, which may not be strongly impacted by lifestyle at this young age. However, other research has shown the benefits of healthy choices on other late effects, such as protecting cardiac wellbeing, so it is still important for clinicians to encourage — and patients to seek — a healthy lifestyle." This underscores that while lifestyle’s direct contribution to secondary cancer risk might be delayed, its overall importance for the holistic health and wellbeing of survivors remains undisputed, impacting other critical late effects of treatment.
Expert Perspectives: A Shift in Understanding
The implications of this research are profound, necessitating a recalibration of how clinicians assess and manage the long-term health of childhood cancer survivors. "Historically, we have paid attention to survivors’ treatment exposures when determining second cancer risk," Dr. Sapkota explained. "Our study suggests that we need to better account for genetic predisposition in this population." This shift implies a move towards a more holistic and personalized risk assessment model.
Survivors with a strong genetic predisposition, identified through advanced genetic sequencing and polygenic risk scores, could benefit from more regular and intensive cancer screenings. Early detection significantly increases the likelihood of successful treatment, potentially mitigating the impact of secondary cancers. Furthermore, empowering survivors with knowledge of their unique combination of treatment-related, genetic, and lifestyle risk factors allows them to become more proactive advocates for their own health, engaging in informed discussions with their healthcare providers about the necessity of specific screenings and preventative measures.
Implications for Clinical Care and Survivor Advocacy
The findings of this St. Jude study are poised to catalyze significant changes in clinical guidelines and the delivery of survivorship care. The future of long-term follow-up for childhood cancer survivors will likely involve:
- Personalized Risk Stratification: Moving beyond a "one-size-fits-all" approach, clinicians will increasingly integrate genetic information, including polygenic risk scores, with detailed treatment histories to create highly individualized risk profiles for each survivor.
- Tailored Screening Protocols: Those identified as having a higher genetic predisposition for specific secondary cancers may be recommended for earlier, more frequent, or more intensive surveillance using advanced imaging and biomarker screening. For example, a young female survivor with a high polygenic risk score for breast cancer, in addition to chest radiation exposure, might begin mammography or MRI screening earlier than current guidelines suggest.
- Genetic Counseling: The study highlights the growing importance of genetic counseling services for childhood cancer survivors and their families. This would involve explaining their genetic risks, discussing implications for screening and prevention, and addressing potential implications for family members.
- Enhanced Patient Education and Empowerment: Survivors equipped with a comprehensive understanding of their personal risk factors can better partner with their healthcare teams. This empowers them to ask informed questions, adhere to personalized screening schedules, and make proactive health decisions.
- Refined Treatment Planning: In the long term, these insights might even influence initial treatment choices for newly diagnosed pediatric cancer patients, guiding decisions towards therapies that minimize long-term secondary cancer risk for genetically susceptible individuals, where clinically appropriate.
Paving the Way for Future Research and Prevention
This study represents a crucial step, but it also opens avenues for extensive future research. Scientists will likely focus on refining polygenic risk scores to enhance their predictive precision for various secondary cancer types in the survivor population. Further investigation into gene-environment interactions—how specific genetic predispositions interact with different chemotherapy agents or radiation fields—will provide even more granular insights. Research into novel preventative strategies, including chemoprevention for high-risk individuals, could also emerge.
Ultimately, the goal remains singular: to extend and enrich the lives of childhood cancer survivors. "Second cancers remain the leading cause of mortality for childhood cancer survivors," Dr. Sapkota reiterated. "Now that we have quantified the contributions of treatment, genetics and lifestyle to the risk of secondary disease, we have a better understanding of where to focus efforts to prevent, detect and treat these cancers, and hopefully extend these survivors’ lives." This scientific breakthrough provides a clearer roadmap for clinicians, researchers, and survivors alike in navigating the complex landscape of long-term survivorship.
Collaborative Science and Funding
The collaborative nature of this extensive research effort involved numerous institutions and dedicated scientists. The study’s first author is Achal Neupane, of St. Jude. Other authors from St. Jude include Siddhant Taneja, Jennifer French, Matthew Ehrhardt, Tara Brinkman, Rachel Webster, Jun Yang, Kirsten Ness, Melissa Hudson, Gregory Armstrong, Leslie Robison, and Yutaka Yasui. Additional contributors include Qi Liu from the University of Alberta; Cindy Im, Lucie Turcotte, and Joseph Neglia from the University of Minnesota; Monica Gramatges from Baylor College of Medicine; Rebecca Howell from the University of Texas MD Anderson Cancer Center; and Smita Bhatia from the University of Alabama at Birmingham.
The study received critical financial support from grants provided by the National Cancer Institute (R01HL173881, R01CA216354, R21CA261833, U24CA55727, U01CA195547, and CA21765). Essential funding also came from ALSAC, the fundraising and awareness organization dedicated to supporting St. Jude Children’s Research Hospital’s mission. This broad base of support underscores the recognized importance of this research in addressing a critical public health challenge for a vulnerable population.
